drug_type
RELEVANT_DRUG
intervention_type
monoclonal antibody
drug_description
Fully human anti-EGFR monoclonal antibody that binds EGFR on tumor epithelial cells, blocking downstream MAPK/PI3K signaling and inhibiting proliferation.
nci_thesaurus_concept_id
C200194
nci_thesaurus_definition
A human recombinant immunoglobulin G1 (IgG1) monoclonal antibody directed against epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon administration, ametumumab targets, binds to and prevents the activation of EGFR. This inhibits EGFR-mediated signaling and proliferation of EGFR-expressing tumor cells. In addition, ametumumab may induce antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) against EGFR-expressing tumor cells. EGFR, a member of the epidermal growth factor receptor family, is overexpressed on various tumor cell types.
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Fully human IgG1 monoclonal antibody targeting EGFR; binds and blocks EGFR activation to inhibit downstream MAPK/ERK and PI3K/AKT signaling, suppressing tumor cell proliferation and survival; may also induce ADCC and CDC against EGFR-expressing cells.
drug_name
Ametumumab
nct_id_drug_ref
NCT05684211